Bullisch
$115.59
Szenariopreis
$86.240
-6.606 (-7.66%)Zum Schluss
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
Merit Medical Systems Inc is a good buy right now due to its strong recent performance, including a 9.5% year-over-year revenue growth in Q2 2026, with total revenue reaching $418.8 million. Additionally, the forward P/E ratio of 18.94 suggests potential for growth compared to its current price of $93.30. However, the risk of insider selling has increased by 1341.20% over the last month, which could indicate potential concerns about future performance.
Barrington
$116
2026-10-30
Barrington
2026-10-30
Kursziel
$116
JPMorgan
$110
2026-10-30
JPMorgan
2026-10-30
Kursziel
$110
Canaccord
$121
2026-10-30
Canaccord
2026-10-30
Kursziel
$121
BTIG
$110
2026-10-30
BTIG
2026-10-30
Kursziel
$110
Needham
$106
2026-10-30
Needham
2026-10-30
Kursziel
$106
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

Investment Opportunities and Risks in Small-Cap Stocks

Merit Medical to Participate in Multiple Investor Conferences

Merit Medical to Participate in Investor Conferences

Merit Medical to Participate in Upcoming Investor Conferences

Merit Medical Systems Reports Strong Q2 2026 Earnings Growth
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Merit Medical Systems Inc is a good buy right now due to its strong recent performance, including a 9.5% year-over-year revenue growth in Q2 2026, with total revenue reaching $418.8 million. Additionally, the forward P/E ratio of 18.94 suggests potential for growth compared to its current price of $93.30. However, the risk of insider selling has increased by 1341.20% over the last month, which could indicate potential concerns about future performance.
9 analysts cover MMSI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 104.63.
Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.